Albumin Fusion Proteins
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
Citations
37 Claims
-
1-23. -23. (canceled)
-
24. A method for treating or preventing at least one cardiovascular disorder in a patient in need thereof comprising administering to said patient an albumin fusion protein comprising two or more tandemly oriented Glucagon-Like Peptide 1 (GLP-1) polypeptides, wherein (i) said GLP-1 polypeptides are selected from wild-type GLP-1,GLP-1 fragments, and GLP-1 variants, fused to albumin comprising the amino acid sequence of SEQ ID NO:
- 1038, an albumin fragment, or albumin variant thereof, (ii) said albumin fragment or albumin variant increases the serum plasma half-life of the GLP-1 polypeptides, and (iii) said fusion protein has GLP-1 activity.
- View Dependent Claims (25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
-
25. The method of claim 24, wherein said GLP-1 fragments or GLP-1 variants are selected from two tandemly oriented GLP-1 (7-36(A8G)).
-
26. The method of claim 25, wherein said two tandemly oriented GLP-1 (7-36(A8G)) are fused at the N-terminus of albumin.
-
27. The method of claim 24, wherein said albumin fusion protein is produced from a host cell comprising a construct which expresses said albumin fusion protein, and wherein said construct is selected from:
- a. 2900;
b. 2964;
c. 2803;
d. 2804;
e. 2945;
f. 2982;
g. 3070;
h. 3027;
i. 3028;
j. 3045;
k. 3046;
l. 3069;
m. 3071;
n. 3072;
o. 3085;
p. 3086;
q. 3087;
r. 3309; and
s. 2904.
- a. 2900;
-
28. The method of claim 24, wherein the albumin fusion protein is in a composition comprising a pharmaceutically acceptable carrier.
-
29. The method of claim 24 wherein said cardiovascular disorder is selected from the group of:
- arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome.
-
30. The method of claim 29 wherein said congenital heart defect is selected from the group of:
- aortic coarctation, cortriatriatum, coronary vessel anomalies, dextrocardia, patent ductus arteriosus, Ebstein'"'"'s anomaly, Eisenmenger complex, hypoplastic left heart syndrome, dextrocardia, tetralogy of Fallot, transposition of the great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher'"'"'s syndrome, patent foramen ovale, and atrial or ventricular septal defects.
-
31. The method of claim 24, wherein said cardiovascular disorder is selected from the group of:
- chronic cardiac failure, heart disease, arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis, heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, pulmonary edema, cardiac hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis, pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, cardiovascular pregnancy complications, Scimitar Syndrome, and cardiovascular infection.
-
32. The method of claim 31 wherein the arrhythmia is selected from the group of:
- sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine syndrome, pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, atrial and ventricular tachycardias, and ventricular fibrillation.
-
33. The method of claim 31 wherein tachycardias is selected from the group of:
- paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.
-
34. The method of claim 31 wherein the heart valve disease is selected from the group of:
- aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.
-
35. The method of claim 31 wherein the myocardial disease is selected from the group of:
- alcoholic cardiomyopathy, diabetic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.
-
36. The method of claim 31 wherein the myocardial ischemia is selected from the group of:
- coronary artery disease, angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction, myocardial stunning, unstable angina, and acute coronary syndrome.
-
37. The method of claim 24 wherein the cardiovascular disease is selected from the group of:
- aneurysms, angiodysplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber syndrome, Sturge-Weber syndrome, angioneurotic edema, aortic diseases, Takayasu'"'"'s Arteritis, aortitis, Leriche'"'"'s syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud'"'"'s disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.
-
25. The method of claim 24, wherein said GLP-1 fragments or GLP-1 variants are selected from two tandemly oriented GLP-1 (7-36(A8G)).
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeHuman Genome Sciences Incorporated (GSK plc), Delta Biotechnology Limited (Sartorius AG)
-
Original AssigneeHuman Genome Sciences Incorporated (GSK plc), Delta Biotechnology Limited (Sartorius AG)
-
InventorsRosen, Craig A., Haseltine, William A., Ruben, Steven M.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/1.9
-
CPC Class CodesA61K 31/155 Amidines (), e.g. guanidine...A61K 31/426 1,3-ThiazolesA61K 31/4439 containing a five-membered ...A61K 31/4965 Non-condensed pyrazinesA61K 38/00 Medicinal preparations cont...A61K 38/04 Peptides having up to 20 am...A61K 38/17 from animals; from humans e...A61K 38/28 InsulinsA61K 39/21 Retroviridae, e.g. equine i...A61P 1/02 Stomatological preparations...A61P 1/04 for ulcers, gastritis or re...A61P 1/16 for liver or gallbladder di...A61P 1/18 for pancreatic disorders, e...A61P 11/00 Drugs for disorders of the ...A61P 11/02 Nasal agents, e.g. deconges...A61P 11/06 AntiasthmaticsA61P 13/02 of urine or of the urinary ...A61P 13/08 of the prostateA61P 13/10 of the bladderA61P 13/12 of the kidneysA61P 15/00 : Drugs for genital or sexual...A61P 15/08 : for gonadal disorders or fo...A61P 15/10 : for impotenceA61P 17/00 : Drugs for dermatological di...A61P 17/02 : for treating wounds, ulcers...A61P 19/02 : for joint disorders, e.g. a...A61P 19/04 : for non-specific disorders ...A61P 19/06 : Antigout agents, e.g. antih...A61P 19/08 : for bone diseases, e.g. rac...A61P 21/00 : Drugs for disorders of the ...A61P 21/04 : for myasthenia gravisA61P 25/00 : Drugs for disorders of the ...A61P 25/10 : for petit-malA61P 25/16 : Anti-Parkinson drugsA61P 25/28 : for treating neurodegenerat...A61P 27/02 : Ophthalmic agentsA61P 27/06 : Antiglaucoma agents or mioticsA61P 27/16 : OtologicalsA61P 29/00 : Non-central analgesic, anti...A61P 3/00 : Drugs for disorders of the ...A61P 3/04 : Anorexiants; Antiobesity ag...A61P 3/06 : AntihyperlipidemicsA61P 3/08 : for glucose homeostasis pan...A61P 3/10 : for hyperglycaemia, e.g. an...A61P 3/12 : for electrolyte homeostasisA61P 3/14 : for calcium homeostasis vit...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/10 : AntimycoticsA61P 31/12 : AntiviralsA61P 31/14 : for RNA virusesA61P 31/16 : for influenza or rhinovirusesA61P 31/18 : for HIVA61P 31/20 : for DNA virusesA61P 31/22 : for herpes virusesA61P 33/00 : Antiparasitic agentsA61P 33/02 : Antiprotozoals, e.g. for le...A61P 33/06 : AntimalarialsA61P 35/00 : Antineoplastic agentsA61P 35/02 : specific for leukemiaA61P 35/04 : specific for metastasisA61P 37/02 : ImmunomodulatorsA61P 37/04 : ImmunostimulantsA61P 37/06 : Immunosuppressants, e.g. dr...A61P 37/08 : Antiallergic agents antiast...A61P 43/00 : Drugs for specific purposes...A61P 5/00 : Drugs for disorders of the ...A61P 5/06 : of the anterior pituitary h...A61P 5/14 : of the thyroid hormones, e....A61P 5/40 : Mineralocorticosteroids, e....A61P 5/50 : for increasing or potentiat...A61P 7/00 : Drugs for disorders of the ...A61P 7/04 : Antihaemorrhagics; Procoagu...A61P 7/06 : AntianaemicsA61P 7/12 : Antidiuretics, e.g. drugs f...A61P 9/00 : Drugs for disorders of the ...A61P 9/02 : Non-specific cardiovascular...A61P 9/04 : Inotropic agents, i.e. stim...A61P 9/06 : AntiarrhythmicsA61P 9/08 : Vasodilators for multiple i...A61P 9/10 : for treating ischaemic or a...A61P 9/12 : AntihypertensivesA61P 9/14 : Vasoprotectives; Antihaemor...C07K 14/005 : from virusesC07K 14/435 : from animals; from humansC07K 14/4713 : Autoimmune diseases, e.g. I...C07K 14/4723 : Cationic antimicrobial pept...C07K 14/475 : Growth factors; Growth regu...C07K 14/50 : Fibroblast growth factor [FGF]C07K 14/505 : Erythropoietin [EPO]C07K 14/51 : Bone morphogenetic factor; ...C07K 14/521 : ChemokinesC07K 14/525 : Tumour necrosis factor [TNF]C07K 14/535 : Granulocyte CSF; Granulocyt...C07K 14/54 : Interleukins [IL]C07K 14/5406 : IL-4C07K 14/55 : IL-2C07K 14/555 : Interferons [IFN]C07K 14/56 : IFN-alphaC07K 14/565 : IFN-betaC07K 14/575 : Hormones derived from pro-o...C07K 14/57563 : Vasoactive intestinal pepti...C07K 14/5759 : Products of obesity genes, ...C07K 14/585 : CalcitoninsC07K 14/59 : Follicle-stimulating hormon...C07K 14/60 : Growth hormone-releasing fa...C07K 14/605 : GlucagonsC07K 14/61 : Growth hormone [GH], i.e. s...C07K 14/62 : InsulinsC07K 14/635 : Parathyroid hormone, i.e. p...C07K 14/65 : Insulin-like growth factors...C07K 14/655 : SomatostatinsC07K 14/665 : derived from pro-opiomelano...C07K 14/705 : Receptors; Cell surface ant...C07K 14/7151 : for tumor necrosis factor [...C07K 14/765 : Serum albumin, e.g. HSAC07K 14/82 : Translation products from o...C07K 16/00 : Immunoglobulins [IGs], e.g....C07K 16/241 : Tumor Necrosis FactorsC07K 16/26 : against hormones ; against ...C07K 2317/10 : characterized by their sour...C07K 2317/622 : Single chain antibody (scFv)C07K 2317/76 : Antagonist effect on antige...C07K 2319/00 : Fusion polypeptideC07K 2319/20 : containing a tag with affin...C07K 2319/30 : Non-immunoglobulin-derived ...C07K 2319/31 : fusions, other than Fc, for...C07K 7/06 : having 5 to 11 amino acidsC12N 15/62 : DNA sequences coding for fu...C12N 2501/335 : Glucagon; Glucagon-like pep...C12N 2740/16111 : concerning HIV envC12N 2740/16122 : New viral proteins or indiv...C12N 2740/16134 : Use of virus or viral compo...C12N 2740/16171 : Demonstrated in vivo effectC12N 7/00 : Viruses; Bacteriophages; Co...C12N 9/0006 : acting on CH-OH groups as d...C12N 9/0008 : acting on the aldehyde or o...C12Y 101/01105 : Retinol dehydrogenase (1.1....C12Y 102/01 : with NAD+ or NADP+ as accep...C12Y 207/01095 : Kanamycin kinase (2.7.1.95)...